The Beneficial Effects of n-3 Polyunsaturated Fatty Acids on Diet Induced Obesity and Impaired Glucose Control Do Not Require Gpr120

Mikael Bjursell1*, Xiufeng Xu1, Therése Admyre1, Gerhard Böttcher1, Sofia Lundin1, Ralf Nilsson1, Virginia M. Stone2, Noel G. Morgan2, Yan Y. Lam4, Leonard H. Storlien3, Daniel Lindén1, David M. Smith1, Mohammad Bohlooly-Y1, Jan Oscarsson1

1. AstraZeneca R&D, Mölndal, Sweden, 2. University of Exeter Medical School, RILD Building, Barrack Road, Exeter, EX2 5DW, United Kingdom, 3. University of Sydney, Sydney, Australia, 4. Pennington Biomedical Research Centre, Baton Rouge, Louisiana, United States of America

*miakel.bjursell@astrazeneca.com

Abstract

GPR120 (Ffar4) has been postulated to represent an important receptor mediating the improved metabolic profile seen upon ingestion of a diet enriched in polyunsaturated fatty acids (PUFAs). GPR120 is highly expressed in the digestive system, adipose tissue, lung and macrophages and also present in the endocrine pancreas. A new Gpr120 deficient mouse model on pure C57bl/6N background was developed to investigate the importance of the receptor for long-term feeding with a diet enriched with fish oil. Male Gpr120 deficient mice were fed two different high fat diets (HFDs) for 18 weeks. The diets contained lipids that were mainly saturated (SAT) or mainly n-3 polyunsaturated fatty acids (PUFA). Body composition, as well as glucose, lipid and energy metabolism, was studied. As expected, wild type mice fed the PUFA HFD gained less body weight and had lower body fat mass, hepatic lipid levels, plasma cholesterol and insulin levels and better glucose tolerance as compared to those fed the SAT HFD. Gpr120 deficient mice showed a similar improvement on the PUFA HFD as was observed for wild type mice. If anything, the Gpr120 deficient mice responded better to the PUFA HFD as compared to wild type mice with respect to liver fat content, plasma glucose levels and islet morphology. Gpr120 deficient animals were found to have similar energy, glucose and lipid metabolism when fed HFD PUFA compared to wild type mice. Therefore, GPR120 appears to be dispensable for the improved metabolic profile associated with intake of a diet enriched in n-3 PUFA fatty acids.
Introduction

GPR120 is a G-protein coupled receptor that is highly expressed in the human and rodent digestive system, notably, though not exclusively, in enteroendocrine L-cells [1]. In the intestine, GPR120 mediates free fatty acid (FFA) stimulated release of glucagon-like peptide 1 (GLP1) that increases glucose stimulated insulin secretion (GSIS), enhances β-cell mass and reduces gastric emptying and appetite [2]. Germ free mice given access to intralipid emulsions display significantly reduced intestinal expression of GPR120, indicating that expression of this receptor is dependent on the intestinal lipid content and microbiota [3]. In addition to its role in the intestine, GPR120 is also expressed in adipose tissue, lung, pro-inflammatory macrophages and islets of Langerhans [2,4–6]. GPR120 was recently shown to be expressed in the delta-cells of the islets of Langerhans mediating a negative effect on glucose stimulated somatostatin secretion [7] as well as in alpha-cells mediating the fatty acid induced secretion of glucagon [8].

Long chain fatty acids (LCFAs) are preferred ligands for GPR120 [2,9,10] [5,11]. The most potent GPR120 ligands are n-3 polyunsaturated fatty acids (PUFAs), such as α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [5,11]. However, also n-6 PUFA and saturated fatty acids are able to activate the receptor [2,8].

Mice deficient in Gpr120 have been developed and studied in relation to diet-induced obesity and insulin resistance [5,6] [8]. Oh et al. performed studies on Gpr120 deficient mice having a mixed 129Sv/C57BL/6 genetic background and exon 2 replaced by a neomycin selection marker. The Gpr120 deficient mice, showed impaired glucose tolerance, increased insulin secretion, as well as hepatic and skeletal muscle insulin resistance on normal chow diet (containing exogenous ω-3 lipids) despite having unaltered body weights [5]. Both WT and Gpr120 deficient mice were similarly susceptible to the development of insulin resistance when fed a HFD without n-3 PUFA supplementation [5]. However, unlike their wild type counterparts, Gpr120 deficient mice did not display improvements in insulin sensitivity and hepatic lipid content when fed a high fat diet (HFD) supplemented with n-3 PUFA [5]. The findings by Oh and co-workers suggested that GPR120 is necessary for the beneficial effects of n-3 PUFA on glucose control and insulin action and, as such, supported earlier observations on the effects of n-3 PUFA [12,13] and reviewed in [14,15]. It was recently shown that Gpr120 deficient mice from the same provider as used by Oh et al. [5], and back-crossed to C57bl/6, had higher body weight gain on chow diet [8]. On HFD diet, the Gpr120 deficient animals were heavier than controls at younger age, but the difference disappeared at 4 months of age. Moreover, they showed an increased glucagon secretion and sensitivity that could help to explain the observation of higher plasma glucose levels and impaired glucose tolerance in the Gpr120 deficient mice. It was concluded that the Gpr120 deficient mice were hyperglycaemic and glucose intolerant because of an hyperactive counter-regulatory response rather than insulin resistance [8]. Another study have reported the phenotype of a different Gpr120 deficient mouse line generated on a
mixed 129Sv/C57BL/6 genetic background with exon 1 in the Gpr120 locus replaced by a neomycin resistance selection marker [6]. These Gpr120 deficient mice were not different from wild-type controls with respect to body weight, fasting plasma glucose or insulin levels when fed a chow diet. However, when fed a 60% HFD with similar amounts of saturated and mono-unsaturated lipids and low n-3 fatty acids, the Gpr120 deficient mice displayed higher body weight, body fat mass and liver fat as well as elevated fasting plasma glucose and insulin levels as compared to the control mice [6]. In summary, the combined results from published studies do not give a clear picture of the role of GPR120 for the effects of n-3PUFA in relation to saturated long-chain fatty acids.

In the present study, a new independent Gpr120 deficient mouse line was developed on a pure C57bl/6N genetic background with exon 1 disrupted by an ATG-LacZ gene fusion and without carrying any antibiotic selection marker. These mice have been used recently to investigate the distribution of the receptor, especially in the islets of Langerhans, and importance of GPR120 for the regulation of somatostatin and insulin secretion [7]. The mice in the present study were fed either a HFD based on lard and palm oil in which most lipids are saturated fatty acids (SAT HFD) or alternatively they were fed a HFD based on Menhaden oil, which contains predominantly n-3 polyunsaturated fatty acids (PUFA HFD). The primary aim of the study was to investigate the effects of the PUFA diet as compared to the saturated fat diet in wild-type (WT) mice and in Gpr120 deficient mice.

**Material and Methods**

**Generation of Gpr120 null mice**

All experiments were approved by Gothenburg Ethics Committee for Experimental Animals.

The targeting strategy of the mouse Gpr120 gene is described under [S1 Supplementary experimental procedures](#) and illustrated in [S1A Fig](#). In short, a 0.567 kb fragment of the coding sequence (CDS) within exon 1 was replaced in frame by a nuclear βGal (nβGal) expression cassette and a loxP floxed PGKneo selection marker gene. This resulted in the deletion of transmembrane domains 1–4 of the GPR120 protein and allowed the expression of nβGal to be driven by the endogenous Gpr120 promoter. The mice were genotyped by PCR using primers amplifying a wild type allele (0.299 kb fragment) and the null allele (0.580 kb fragment), forward: 5'-GCTTTCATATGGGGTTACTCG-3'; reverse: 5'-ACTTG-GCACTGTGGGTAAACT-3'; 732, forward: 5'-TGAAGGCTCTTTACTATTGCT-3'. Tissue samples from lung, liver and skeletal muscle were dissected from 8 week old wild type, Gpr120 heterozygous and Gpr120 homozygous littermates. Total RNA was extracted with TRIZol Reagent (Invitrogen) according to the manufacturer’s protocol. Reverse transcription was performed with SuperScript First-Strand (Invitrogen) followed by PCR using primers located in 5' UTR of exon 1 of Gpr120 and within downstream intact exons, forward: 5'-ATGAGCGC-
TCTTCAGACAGC-3'; reverse: 5'-GCCAATCCAATGTGCAAATCG-3'; forward: 5'-ATTGGCCCAACCGCATAGGAG-3' and reverse: 5'-TCATTTCGCCTGACAGACGTA-3' (Fig. 1A). Tissue X-gal staining experiment was performed as described previously [16] but the tissues were stained at 37°C over night (Fig. 1B).

Animal experiments
The Gpr120 heterozygous mouse colony was expanded by breeding to C57Bl/6N mice (Charles River) and heterozygous intercross was performed to produce experimental (Gpr120 KO) and wild type (WT) littermate control cohorts, having a pure C57bl/6N genetic background. Male Gpr120 KO and WT littermates were housed individually in a temperature controlled room (22°C) with a 12 hour light-dark cycle. They had access to a normal chow diet (R36, Lactamin AB, Stockholm, Sweden) and water ad libitum. The R36 chow diet contained (weight %): 3.5% cellulose, (energy %): 22.9% protein, 67.1% carbohydrate and 9.6% fat.

The main sources of proteins were from soy, grain and potatoes. Carbohydrate source was mainly grains and the main fat source was soy beans. Fatty acid composition of the R36 chow diet is the following; C16:0~18%; C18:1 n9~16%; C18:2 n6~53%; C18:3 n3~5% (remaining n3 FAs <0.1%). The energy density of R36 is 3.08 kcal/g. During high fat diet (HFD) feeding, two different HFD were used (Research Diets Inc., New Brunswick, USA). Both diets had the following energy source composition (energy %): proteins 20%; carbohydrates 35%, lipids 45% and an energy density of 4.73 kcal/g. The lipids from the polyunsaturated (PUFA) HFD were derived from Menhaden oil and contained 29% saturated fat, 24% monounsaturated fat and 47% polyunsaturated fat, resulting in 11 g/kg n-6 lipids, 75 g/kg n-3 lipids and an n-6/n-3 ratio of 0.14. The lipids from the saturated (SAT) HFD were derived from lard (50%) and palm oil (50%) and contained 42% saturated fat, 45% monounsaturated fat and 13% polyunsaturated fat, resulting in 27 g/kg n-6 lipids, 2 g/kg n-3 lipids and an n-6/n-3 ratio of 15.33. Detailed information on the diets is presented in S1 Table.

The mice were initially fed the normal R36 chow diet. At 13 weeks of age, they were subdivided into two groups, and 1 cohort of Gpr120 KO mice (n=7) and 1 cohort of WT mice (n=8) were switched to the SAT HFD while a second cohort of Gpr120 KO mice (n=7) and WT mice (n=8) were switched to the PUFA HFD. The HFD was provided to all animals over an 18 week period. Separate groups of WT (n=8) and Gpr120 KO (n=8) mice were fed R36 chow diet for 16 weeks before their body composition was analysed.

All mice were terminated at 31 weeks of age, 18 weeks after the introduction of their respective HFDs. The mice were fasted for 3 hours, then anaesthetised by isoflurane inhalation and blood was collected in EDTA-coated tubes by cardiac puncture. Blood plasma was separated by centrifugation (2500 rpm (664 g), 10 min. 4°C) and snap frozen in liquid nitrogen. Liver tissue samples were taken for hepatic triglyceride content analysis [17]. Tissue samples of liver, epididymal WAT and pancreas were processed for histological analysis by immersion fixation.
in 4% buffered formaldehyde solution for 24–48 hours, dehydrated in graded series of alcohol and embedded in paraffin, sectioned and stained.

**Body weight, indirect calorimetry, locomotor activity, food intake, body temperature and composition**

Body weights of the Gpr120 KO and WT mice were recorded on a weekly basis from 4 weeks of age up to 23 weeks of age and then finally at 31 weeks of age.
Body length (nose to base of the tail) was assessed at 23 weeks of age. Assessment of indirect calorimetry, water consumption and locomotor activity was performed at 22–23 weeks of age (10 weeks after HFD introduction) in a CLAMS system (Columbus Instruments, Columbus, USA) at thermoneutral temperature (set for WT mice to be 29.5°C) as previously described [18]. The mice were placed in the CLAMS calorimeter chambers with ad libitum access to diet and water for 72 hours. Energy intake was analysed over 48 hours in food deprived mice (12 hours) as previously described [19] with a minor modification: no initial incubation (80°C for 1 hour) of the cages was done. Total faeces produced over the measurement periods were collected and the energy content of the faeces was determined with a bomb calorimeter (C 5000, IKA® Werke GmbH & Co. KG, Germany). Rectal core body temperatures were recorded in conscious non-anaesthetised mice during day time (10.00–11.00 am) using a rectal probe [18]. Body composition was assessed by dual energy X-ray absorptiometry (DEXA, GE Lunar, Madison, USA) in Isoflurane anaesthetised mice as previously described [18].

**Oral glucose tolerance test (OGTT)**

OGTT was performed 14 weeks after respective HFD introduction as previously described [20]. Fasting blood glucose level times fasting insulin level was calculated \[\text{fasting blood glucose (mM) x fasting blood insulin (ng/ml)}\] as an index of insulin resistance.

**Plasma analysis**

Plasma levels of cholesterol, triglyceride, leptin, adiponectin, alanine aminotransferase (ALT) and albumin were determined as previously described [17]. Plasma levels of fructosamine were measured using an enzymatic colorimetric method (Kit No FR2992, Randox Laboratories Ltd, UK) and assays were performed on an ABX Pentra 400 (Horiba ABX, France). Total bilirubin was measured using a colorimetric method (Kit No 11552414 216; BIL-T, Roche Diagnostics GmbH, Germany). Plasma lipids were extracted as described previously [21] and explained in detail under S1 Supplementary experimental procedures. Individual fatty acids, including, C14:0, C16:0, C16:1n-9, C18:0, C18:1n-9, C18:2n-6, C18:3n-3 (ALA), C20:4n-6, C20:5n-3 (EPA), C22:6n-3 (DHA) were quantified by calculating area response versus the internal standard.

**Histology**

Epididymal WAT macrophage staining and semi quantitative assessment were performed on histological sections as previously described using an anti-Mac2/ galectin3 antibody [17]. Adipocytes were also double stained with Perilipin and Mac2/galectin3 antibodies, details are outlined in S1 Supplementary experimental procedures. Histopathological examination and evaluation of liver tissue
samples was performed on hematoxylin-eosin (H&E) stained sections and degree of steatosis and inflammation was scored on a semi quantitative 5 grade scale. Serial sections of paraffin embedded pancreases were employed for immunostaining and were prepared from WT mice fed chow (n=3 separate group), SAT HFD or PUFA HFD and from Gpr120 KO mice fed chow (n=3 separate group), SAT HFD or PUFA HFD. Sections were stained with anti-insulin (Dako Cytomation, Ely, UK) and anti-Mac2 (Cederlane Labs, Ontario, Canada) antibodies (DAKO, Ely, UK) using standard immunoperoxidase technique (see S1 Supplementary experimental procedures). Slides were examined by light microscopy and quantitative analysis carried out using randomly selected islets from each section. The number of Mac2/galectin3 positive cell profiles (indicating the number of macrophages) present within the islet profile or in the peri-islet area was recorded. The area of each islet was measured using ImageJ software.

Statistical analysis
All values are given as group means ± SEM. Statistical analyses was performed using 1-way ANOVA and if significant (p<0.05) followed by pair-wise comparison using Student’s t-test between the two HFD groups in WT and Gpr120 KO mice, respectively. The other 4 possible comparisons were not tested. Statistical calculations of parameters measured over time were done by a 2-way ANOVA using time and diet as factors or alternatively calculating AUC for each observation and then applying 1-way ANOVA. Data was log normalized when appropriate. p<0.05 between the groups was considered to be statistically significant differences.

Results
Gpr120 null animals were generated by targeted deletion of a part of exon 1 in the Gpr120 locus (S1A Fig.). Gpr120 deficiency was confirmed by RT-PCR analyses, designed to amplify fragments both within and outside the deleted DNA sequence, using RNA derived from skeletal muscle, liver and lung tissue from wild type, heterozygous and homozygous Gpr120 KO mice. As expected, no expression of Gpr120 was observed in the homozygous Gpr120 KO mice (Fig. 1A). The construct design was validated by LacZ expression in which blue staining was observed in tissue sections where GPR120 is known to be present upon incubation with X-gal. Staining was observed in the lung and the intestine of Gpr120 deficient mice but was absent from all tissues in WT mice (Fig. 1B). Slides from intestine and lungs clearly show positive staining in enteroendocrine cells and goblet cells, respectively (Fig. 1C). Intercrossing of male and female mice heterozygous for the Gpr120 mutation resulted in offspring of normal litter sizes. Among the male offspring; 26% were homozygous for the deletion, 48% were heterozygous and 26% were wild type.
Body weight and body composition

No significant differences in body weight gain were observed between Gpr120 KO \((n=14)\) and WT \((n=16)\) mice on chow diet at any time point up to 13 weeks of age \((\text{Fig. 2A})\). Moreover, body composition was assessed by DEXA in a separate cohort of chow fed Gpr120 KO and WT mice at 16 weeks of age. At that time, there was no significant difference in absolute and relative measures of body lean mass, body fat mass, bone mineral content (BMC) or bone mineral density (BMD) \((\text{data not shown})\). The mice in this cohort were also studied with respect to assessment of body weight gain, indirect calorimetry, ECG and a number of behavioural assessments \([18]\) over a 48 week period. No significant differences were observed in any of these assessments between chow fed WT and Gpr120 KO mice \((\text{data not shown})\).

After switching to SAT HFD or PUFA HFD at 13 weeks of age, no significant differences in body weight gain were observed between the WT and Gpr120 KO mice \((\text{Fig. 2B})\). However, PUFA HFD feeding resulted in lower body weight gain in both genotypes. At study termination after 18 weeks on HFDs, the mice fed SAT HFD were more than 20% heavier than the mice on PUFA HFD \((p<0.05)\). Body length did not differ significantly between any of the groups \((\text{data not shown})\).

Assessment of body composition was performed after 11 weeks on HFD \((23\) weeks of age). Both WT and Gpr120 KO mice fed PUFA HFD had significantly lower absolute and relative \((\%\) of body weight) body fat mass compared to WT mice fed the SAT HFD \((\text{Fig. 3})\). Lean body mass was not significantly different between animals on PUFA HFD as compared to SAT HFD in any of the genotypes. Also, no significant effects on bone mineral density (BMD) or bone mineral content (BMC) were observed between mice fed PUFA vs. SAT HFD regardless of genotype. \((\text{Fig. 3})\).

Energy intake, energy expenditure, locomotor activity and core body temperature

The major difference in body composition between mice on PUFA HFD and SAT HFD was body fat mass. Since energy expenditure in adipose tissue is generally relatively low, energy intake and energy expenditure are presented per individual mouse as well as related to lean body mass. Energy intake per mouse \((\text{kcal/day})\) was significantly higher when Gpr120 KO mice were fed PUFA HFD compared to SAT HFD. The same trend was also seen in WT mice on PUFA HFD as compared to SAT HFD \((\text{Table 1})\). Energy intake related to lean body mass was significantly higher in both WT and Gpr120 KO mice on PUFA HFD as compared to SAT HFD. Interestingly, also the faecal energy content was increased when the mice were fed PUFA HFD compared to SAT HFD, but the difference was statistically significant in Gpr120 KO mice only. When taking into account the faecal energy loss, relative energy uptake was significantly higher in PUFA fed WT and Gpr120 KO mice expressed as energy intake per lean body mass. Also relative water intake was higher when the mice were fed PUFA HFD compared to SAT HFD \((\text{Table 1})\).
Mean values for energy expenditure over 72 h was calculated for each individual mouse and presented as mean values for the treatment groups (Fig.4) and values for each 2 h time point during the 72 h period in the CLAMS system are presented in Fig. S2. Energy expenditure expressed per mouse was lower in WT mice on PUFA HFD as compared to WT mice on SAT HFD, while there was no significant difference between the groups of Gpr120 KO mice. However, there was no significant difference in energy expenditure relative to lean body mass.
between mice given PUFA HFD and mice given SAT HFD, neither in WT nor in Gpr120 KO animals. No significant difference was observed in respiratory exchange ratio (RER) between mice fed PUFA HFD and SAT HFD, regardless of genotype (data not shown). Neither locomotor activity nor core body temperature was significantly influenced by the diets in WT and Gpr120 KO mice (data not shown).

Fig. 3. Body composition analyses. Body composition was assessed at 23 weeks of age after 11 weeks of HFD. A; body fat mass, B; body lean mass and C; body bone mineral density (BMD) and content (BMC) in WT mice fed SAT HFD (n=8, filled bars) and PUFA HFD (n=8, open bars) and in Gpr120 KO mice fed SAT HFD (n=7, filled bars) and PUFA HFD (n=7, open bars). Statistical analysis was done by 1-way ANOVA followed by two comparisons (SAT HFD vs. PUFA HFD) using Student’s t-test, *** p<0.001.

doi:10.1371/journal.pone.0114942.g003
Glucose homeostasis
Measurement of fasting plasma levels of glucose and insulin as well as oral glucose tolerance tests (OGTT) were performed 14 weeks after the HFDs were introduced.

Table 1. Energy intake and faecal energy content.

| Parameter                          | Genotype            | WT (n=8) SAT HFD | WT (n=8) PUFA HFD | Gpr120 KO (n=7) SAT HFD | Gpr120 KO (n=7) PUFA HFD | 1-way ANOVA |
|------------------------------------|---------------------|------------------|-------------------|------------------------|------------------------|-------------|
| Energy intake (kcal/day)           |                     | 15.31 ± 1.03     | 17.56 ± 0.88      | 14.93 ± 0.98           | 18.03 ± 0.87**         | p<0.05      |
| Rel. energy intake (kcal/day/g LBM)|                     | 0.66 ± 0.04      | 0.84 ± 0.05*      | 0.70 ± 0.04            | 0.82 ± 0.04*           | p<0.05      |
| Faecal energy content (kcal/day)   |                     | 1.07 ± 0.09      | 1.38 ± 0.14       | 1.14 ± 0.12            | 1.46 ± 0.08*           | p<0.05      |
| Energy uptake (kcal/day)           |                     | 14.24 ± 0.95     | 16.18 ± 0.76      | 13.79 ± 0.88           | 16.57 ± 0.80           | NS          |
| Rel. energy uptake (kcal/day/g LBM)|                     | 0.61 ± 0.04      | 0.78 ± 0.05*      | 0.64 ± 0.04            | 0.75 ± 0.04*           | p<0.05      |
| Water intake (ml/day)              |                     | 2.28 ± 0.19      | 2.69 ± 0.14       | 2.19 ± 0.18            | 3.12 ± 0.39*           | p<0.05      |
| Rel. water intake (ml/day/g LBM)   |                     | 0.098 ± 0.007    | 0.129 ± 0.007**   | 0.104 ± 0.008          | 0.142 ± 0.020          | p<0.05      |

Values are presented as group mean ± SEM. Rel. = relative. LBM = lean body mass. Statistical analysis performed by 1-way ANOVA followed by Students T-test comparing SAT HFD vs. PUFA HFD. Star indicates significant difference between mice fed SAT HFD vs. WT fed PUFA HFD. * p<0.05; ** p<0.01.

doi:10.1371/journal.pone.0114942.t001

Fig. 4. Indirect calorimetry assessment. A: Energy expenditure given in kilocalories per hour per mouse (kcal/h) and B: energy expenditure relative to lean body mass (LBM). The groups are WT fed SAT HFD (n=8) and PUFA HFD (n=8) as well as Gpr120 KO mice fed SAT HFD (n=7) and PUFA HFD (n=7). Mean values for energy expenditure over 72 h was calculated for each individual mouse and the graphs show mean values for the treatment groups. Statistical analysis was performed using 1-way ANOVA followed by Student’s t-test comparing SAT HFD and PUFA HFD in each genotype, * p<0.05.

doi:10.1371/journal.pone.0114942.g004
Both WT and Gpr120 KO had significantly lower fasting insulin levels on PUFA HFD than on SAT HFD. In contrast, Gpr120 KO mice, but not WT mice, had significantly lower fasting plasma glucose levels on PUFA HFD as compared to SAT HFD. An insulin resistance index (glucose (mM) x insulin (ng/ml)) was calculated and it was significantly lower in both groups of mice on PUFA HFD than in those on SAT HFD (Fig. 5A). Oral glucose tolerance was improved in both WT and Gpr120 KO mice fed PUFA HFD compared to SAT HFD (Fig. 5B). In WT mice, blood glucose area under the curve (AUC) was 1714.1 ± 110.5 on PUFA HFD and 2151.4 ± 103.5 on SAT HFD (p<0.05), and in Gpr120 KO mice, blood glucose AUC was 1532.5 ± 47.0 on PUFA HFD and 1817.1 ± 50.6 on SAT HFD (p<0.01). The insulin response measured as AUC was significantly lower following the glucose challenge in both genotypes when fed the PUFA HFD as compared to the SAT HFD. In WT mice, blood insulin AUC was 257.6 ± 53.4 on PUFA HFD and 683.5 ± 107.6 on SAT HFD (p<0.01), and in Gpr120 KO mice, blood insulin AUC was 304.6 ± 50.6 on PUFA HFD and 554.0 ± 84.7 on SAT HFD (p<0.05). The 15 minute insulin response in Gpr120 KO mice on PUFA HFD was more marked and correlated with a trend towards lower blood glucose levels at 30 minutes in the Gpr120 KO mice compared to WT mice on PUFA HFD (Fig. 5B).

**Tissue weights and histology**

Final body weight was 18% lower in WT mice and 12% lower in Gpr120 KO mice on PUFA HFD as compared to the corresponding groups on SAT HFD (Table 2). Interestingly, the relative weights of epididymal and retroperitoneal fat depots tended to be higher in WT animals and was significantly higher in Gpr120 KO animals on PUFA HFD as compared to those on SAT HFD. However, there was no effect on diet or genotype on relative brown adipose tissue (BAT) weights. The relative liver weight was approximately 40% lower in both WT and Gpr120 KO animals on PUFA HFD.

Epididymal white adipose tissue (WAT) was analysed in terms of macrophage content. No significant differences in Mac2 quantified staining were observed between PUFA HFD and SAT HFD fed mice. In WT mice, Mac2 area was 1.14 ± 0.23% on PUFA HFD and 0.98 ± 0.34% on SAT HFD, and in Gpr120 KO mice, the Mac2 area was 0.98 ± 0.21% on PUFA HFD and 0.80 ± 0.22% on SAT HFD (representative slides shown in S3 Fig.). WAT tissue was also double stained with Perilipin and Mac2 to understand how the different pattern of immune markers correlated with dead adipocytes (Fig. 6). As expected, adipose tissue from mice fed SAT HFD displayed high number of ‘crown like’ structures (CLS) surrounding perilipin-free lipid droplets (Fig. 6 and S3 Fig.). Interestingly, staining of the WAT macrophages in mice fed the PUFA HFD revealed the presence of similar numbers of immunopositive macrophages but these displayed a different pattern of Mac2-staining as multinuclear giant cells aggregation (MNGCA) rather than CLS, and only a few of the CLS were observed in samples from the mice fed PUFA HFD (Fig. 6). Most cells on the slides displayed positive
perilipin staining, regardless of genotype and diet. However, WAT tissue slides from mice fed SAT HFD displayed more frequent perilipin negative cells associated with the CLS compared to mice fed PUFA HFD. Slides from PUFA HFD fed mice had less perilipin free cells, indicating that PUFA HFD feeding is associated with fewer dead adipocytes compared to SAT HFD feeding. No differences between genotypes were observed with respect to Mac2 and perilipin staining.

The inferior lobes of the liver were sampled to assess liver triglyceride content and histopathology. WT mice fed PUFA HFD displayed about 70% lower hepatic triglyceride content compared to the SAT HFD fed WT mice. Gpr120 KO mice fed PUFA HFD had close to 90% lower liver triglyceride content compared to Gpr120

Fig. 5. Oral glucose tolerance test. A: Fasting blood insulin, glucose levels and insulin resistance index (glucose (mM) x insulin (ng/ml)) and B: oral glucose tolerance test in WT mice fed SAT HFD (n=8, filled bars, filled square) or PUFA HFD (n=8, open bars, open square) and in Gpr120 KO mice fed SAT HFD (n=7, filled bars, dashed lines filled circle) or PUFA HFD (n=7, open bars, dashed lines open circle). Statistical calculations were based on individual area under the curve (AUC) values, calculated from 0 to 120 minute time points. Statistical analysis was done by 1-way ANOVA followed by two comparisons (SAT HFD vs. PUFA HFD) using Student’s t-test, * p<0.05; ** p<0.01.

doi:10.1371/journal.pone.0114942.g005
KO mice fed the SAT HFD (Fig. 7A). These findings were supported by histopathological examination, which revealed that the PUFA HFD fed mice, regardless of genotype, displayed a lower degree of hepatic steatosis compared to animals fed the SAT HFD. The steatosis was graded from 0 to 5 and mean steatosis grade was 3.9 ± 0.1 in WT and 4.0 ± 0.0 in Gpr120 KO mice on SAT HFD. On PUFA HFD, the steatosis grade was 1.6 ± 0.4 in WT animals and 0.6 ± 0.3 in Gpr120 KO mice. In addition, liver samples from PUFA HFD fed WT and Gpr120 KO mice showed conspicuous sinusoidal Kupffer cells and/or possibly perisinusoidal Ito cells. These cells had a foamy appearance with markedly swollen and slightly basophilic cytoplasm, and they were sometimes surrounded by inflammatory cells (Fig. 7B).

Pancreases were analyzed to determine the average islet area and macrophage content. Separate cohorts of chow fed WT and Gpr120 KO mice were also included to understand islet size and inflammation under normal dietary conditions. No significant difference was observed in islet area between PUFA HFD fed and SAT HFD fed WT mice (Fig. 8A). However, the PUFA HFD fed WT mice displayed lower numbers of macrophages per islet compared to the SAT HFD fed mice (PUFA HFD: 2.09 ± 0.45 cells/islet, SAT HFD: 3.11 ± 0.19; p=0.05). Gpr120 KO mice fed PUFA HFD had significantly lower islet area and

Table 2. Absolute and relative tissue weights.

| Parameter/Genotype | WT (n=8) SAT HFD | WT (n=8) PUFA HFD | Gpr120 KO (n=7) SAT HFD | Gpr120 KO (n=7) PUFA HFD | 1-way ANOVA |
|-------------------|-----------------|------------------|-------------------------|-------------------------|------------|
| Body weight (g)   | 53.50 ± 1.12    | 43.83 ± 3.05*    | 50.03 ± 1.20            | 43.90 ± 2.08*           | p<0.05     |
| Lung (g)          | 0.17 ± 0.00     | 0.18 ± 0.01      | 0.16 ± 0.00             | 0.18 ± 0.01             | NS         |
| Rel. Lung (mg/g bw)| 3.11 ± 0.04     | 4.31 ± 0.29***   | 3.25 ± 0.07             | 4.11 ± 0.07***          | p<0.05     |
| Heart (g)         | 0.19 ± 0.01     | 0.17 ± 0.01      | 0.18 ± 0.00             | 0.18 ± 0.01             | NS         |
| Rel. Heart (mg/g bw)| 3.58 ± 0.11     | 4.03 ± 0.17**    | 3.66 ± 0.07             | 4.12 ± 0.13**           | p<0.05     |
| Epi WAT (g)       | 1.69 ± 0.14     | 1.91 ± 0.23      | 2.07 ± 0.12             | 2.27 ± 0.14             | NS         |
| Rel. Epi WAT (mg/g bw)| 31.81 ± 3.09  | 42.72 ± 4.48     | 41.73 ± 3.44            | 51.54 ± 0.98*           | p<0.05     |
| Retro WAT (g)     | 0.59 ± 0.03     | 0.55 ± 0.07      | 0.62 ± 0.04             | 0.70 ± 0.03             | NS         |
| Rel. RetroWAT (mg/g bw)| 11.00 ± 0.62 | 12.38 ± 1.63     | 12.47 ± 0.98            | 16.08 ± 0.57**          | p<0.05     |
| BAT (g)           | 0.54 ± 0.04     | 0.49 ± 0.07      | 0.51 ± 0.04             | 0.40 ± 0.04             | NS         |
| Rel. BAT (mg/g bw)| 10.08 ± 0.67    | 10.76 ± 1.14     | 10.23 ± 0.62            | 8.95 ± 0.65             | NS         |
| Testis (g)        | 0.22 ± 0.00     | 0.22 ± 0.01      | 0.22 ± 0.01             | 0.22 ± 0.01             | NS         |
| Rel. Testis (mg/g bw)| 4.03 ± 0.11     | 5.29 ± 0.43**    | 4.35 ± 0.17             | 5.11 ± 0.27**           | p<0.05     |
| Liver (g)         | 4.33 ± 0.34     | 2.19 ± 0.22***   | 3.38 ± 0.29             | 1.84 ± 0.07***          | p<0.05     |
| Rel. Liver (mg/g bw)| 80.21 ± 5.09    | 49.60 ± 2.57***  | 67.13 ± 4.62            | 42.20 ± 1.02***         | p<0.05     |
| Kidney (g)        | 0.43 ± 0.02     | 0.42 ± 0.02      | 0.40 ± 0.01             | 0.47 ± 0.03             | NS         |
| Rel. Kidney (mg/g bw)| 8.03 ± 0.28     | 9.84 ± 0.50**    | 8.08 ± 0.13             | 10.75 ± 0.38***         | p<0.05     |

Values are presented as group mean ± SEM. Statistical analysis performed by 1-way ANOVA followed by Students T-test comparing SAT HFD vs. PUFA HFD. Star indicates significant difference between mice fed SAT HFD vs. WT fed PUFA HFD.

* p<0.05; ** p<0.01; *** p<0.001.

WAT; white adipose tissue, Epi; Epididymal, Retro; retroperitoneal, BAT; brown adipose tissue, bw; body weight.

doi:10.1371/journal.pone.0114942.t002
Plasma analysis

Plasma levels of adiponectin were higher and ALAT levels were lower in PUFA HFD fed vs. SAT HFD fed WT and Gpr120 KO mice (Table 3). Plasma leptin levels trended to be lower in PUFA HFD fed mice, but the effect was not statistically significant. Plasma levels of albumin were significantly lower in PUFA HFD fed vs. SAT HFD fed WT mice, but no significant effect of diet on plasma albumin was observed in Gpr120 KO mice. Plasma cholesterol levels were significantly lower and there was a trend towards lower plasma triglyceride levels in the mice fed PUFA HFD compared to mice given SAT HFD. There was no effect of the diets on fructosamine levels. The fatty acid composition of triglycerides, phospholipids and cholesteryl esters were determined in plasma. The content of C20:5n-3 was below the detection limit in the SAT HFD mice and PUFA HFD diet resulted in high levels of this fatty acid. The levels of 22:6n-3 and C18:3n-3 were significantly higher in mice fed PUFA HFD than in mice fed SAT HFD. The mol% of n-3 PUFA (22:6n-3, C20:5n-3, C18:3n-3) was 38.2% and...
39.3% in WT and Gpr120 KO mice fed PUFA HFD respectively, and 7.2 and 9.3% in WT and Gpr120 KO mice fed SAT HFD respectively. Mice fed PUFA HFD, regardless of genotype had increased levels of C14:0 and C16:1, but significantly lower levels of C16:0, C18:0, C18:1n-9, C18:2n-6 and C20:4n-6 compared to mice fed the SAT HFD (Table 3).
Discussion

The n-3 polyunsaturated fatty acids (n-3 PUFAs) are generally considered to be beneficial for a variety of indications, including various aspects of the metabolic syndrome such as dyslipidemia, insulin resistance, endothelial dysfunction and inflammation [15, 22–24]. Recently, GPR120 has been implicated in several processes associated with metabolic regulation and body weight control [2, 5, 6] [8] and, in particular, the receptor has been proposed to mediate the effects of n-3 PUFA on these processes [5]. Against this background, we have investigated the well-known effects of a diet enriched in n-3 PUFA as compared to a diet comprising mainly of saturated and monounsaturated fatty acids on glucose and...
GPR120 Is Not Required for n-3 PUFA Effects on Energy Metabolism

Table 3. Plasma analyses.

| Parameter | Genotype | WT (n=8) SAT HFD | WT (n=8) PUFA HFD | Gpr120 KO (n=7) SAT HFD | Gpr120 KO (n=7) PUFA HFD | 1-way ANOVA |
|-----------|----------|-----------------|-------------------|------------------------|--------------------------|-------------|
| Fructosamine (µM) | 72.49 ± 2.75 | 68.85 ± 5.54 | 70.46 ± 3.69 | 67.30 ± 2.37 | NS |
| C20:5n-6 (µM) | <LLOQ | 163.9 ± 14.6 | <LLOQ | 137.3 ± 6.4 | - |
| C22:6n-3 (µM) | 93.2 ± 4.6 | 129.6 ± 8.2** | 76.5 ± 6.5 | 110.9 ± 5.5** | p<0.05 |
| C14:0 (µM) | 48.4 ± 2.6 | 88.2 ± 3.8*** | 62.3 ± 2.4 | 114.8 ± 7.5*** | p<0.05 |
| C16:0 (µM) | 468.2 ± 29.9 | 207.7 ± 22.1*** | 362.5 ± 34.6 | 165.3 ± 7.6*** | p<0.05 |
| C16:1n-9 (µM) | 20.3 ± 1.6 | 31.8 ± 3.9* | 16.6 ± 1.2 | 28.6 ± 1.9*** | p<0.05 |
| C18:0 (µM) | 282.7 ± 10.2 | 119.1 ± 9.5*** | 230.6 ± 20.0 | 98.0 ± 4.5*** | p<0.05 |
| C18:1n-9 (µM) | 278.2 ± 22.6 | 67.1 ± 13.7*** | 213.4 ± 21.6 | 50.4 ± 4.4*** | p<0.05 |
| C18:2n-6 (µM) | 271.8 ± 15.6 | 22.9 ± 2.1*** | 224.5 ± 21.2 | 18.0 ± 0.9*** | p<0.05 |
| C18:3n-3 (µM) | 43.2 ± 1.1 | 88.7 ± 3.1*** | 63.2 ± 5.1 | 109.1 ± 4.1*** | p<0.05 |
| C20:4n-6 (µM) | 394.8 ± 17.3 | 91.6 ± 3.9*** | 323.9 ± 25.9 | 77.6 ± 2.0*** | p<0.05 |
| % n-3 of total | 7.2 ± 0.2 | 38.2 ± 0.8*** | 9.3 ± 0.5 | 39.3 ± 0.4*** | p<0.05 |

Values are presented as group mean ± SEM. Statistical analyses performed by 1-way ANOVA followed by Students t-test comparing SAT HFD vs. PUFA HFD. Significance tests were made between mice fed SAT HFD vs. mice fed PUFA HFD.

* p<0.05;
** p<0.01;
*** p<0.001.

Percentage of n-3 fatty acids in plasma triglycerides, phospholipids and cholesteryl esters were calculated as sum of 18:3n-3, 20:5n-3 and 22:6n-3 divided by the sum of all detected fatty acids. LLOQ - Lower Limit Of Quantification.

doi:10.1371/journal.pone.0114942.t003

energy metabolism in a newly developed Gpr120 deficient (Gpr120 KO) mouse line. We found that wild type (WT) and Gpr120 KO mice developed a similar level of obesity and impaired glucose control when fed a saturated HFD containing low amounts of n-3 PUFAs. To our surprise, when fed the n-3 PUFA enriched HFD, Gpr120 deficient mice displayed similar body weight, body fat mass, liver fat, energy metabolism and glucose control to WT mice on n-3 PUFA HFD, showing that GPR120 is dispensable for the positive effects of n-3 PUFA on metabolism.

The effects of n-3 PUFA supplementation on body weight regulation and glucose control in rodents are well studied. In accordance with expectation, consumption of a high fat diet (HFD) containing n-3 PUFA resulted in lower body weight gain and adipose tissue mass than feeding of a HFD containing mainly saturated fat in C57Bl/6 mice [25–27]. Similarly, fat-1 transgenic mice that express a desaturase from C. Elegans, which converts n-6 PUFA to n-3 PUFA, also show lower body weight gain [28] as compared to WT mice fed HFD. Our study showed that 11 weeks of PUFA HFD feeding resulted in lower total body fat mass compared to a corresponding group fed SAT HFD. Surprisingly, the weights of
the epididymal and retroperitoneal fat depots were not different between the diets at the time of sacrifice, although the total body weight was about 20% lower in the PUFA HFD fed mice. This finding is in line with increased epididymal fat pad weight in spite of reduced body weight gain in mice on menhaden oil diet in a previous study [27]. Based on our own data and previous studies showing reduced body fat mass following n-3 PUFA supplementation [25, 26], the most likely explanation for the discrepant effect on total body fat mass and unchanged weight of the fat pads is a change in body fat distribution, e.g. reduced subcutaneous and visceral fat mass. 

Even though the present study was not designed to evaluate the effect of a SAT HFD as compared to chow fed mice, it was clearly demonstrated that Gpr120 deficiency did not result in a different body weight on a SAT HFD as compared to WT mice. This finding is in contrast to the reported intolerance to HFD observed by Ichimura et.al. [6]. In contrast to our results, they found that Gpr120 deficient mice given a HFD containing mainly saturated and monounsaturated lipids displayed higher body weight gain, impaired glucose control and hepatic steatosis by comparison to WT mice fed HFD [6]. Suckow et.al. [8] using the same strain of Gpr120 deficient mice as Oh et.al. [5], but back-crossed to C57bl/6, showed that Gpr120 KO mice on HFD were initially heavier than the WT controls, but after 4 months there were no difference in body weight between the genotypes. We have done another study (data not shown) in which we fed WT (n=7) and Gpr120 KO mice (n=9) a HFD with 60% energy from fat (Product nr: 12492, Research Diets Inc.). The mice were on the diet for 25 weeks and body weight gain, body composition, indirect calorimetry, oral glucose tolerance and food intake were recorded. However, none of these parameters were significantly different between WT and Gpr120 KO mice using that diet. Hence, the Gpr120 deficiency model used herein is not associated with an abnormal metabolic phenotype.

Since the effects of n-3 PUFA HFD on food intake and energy expenditure were similar between the genotypes, it is concluded that GPR120 is not obligatory for n-3 PUFA mediated effects on energy metabolism. In spite of increased food intake and energy uptake, also in relation to lean body mass, the PUFA HFD fed mice gained less body weight than the SAT HFD fed mice independent of genotype. Therefore, it is likely that increased energy expenditure explains the lower body weight gain during PUFA HFD as compared to feeding the SAT HFD. The energy expenditure is presented per individual mouse and also relative to lean body mass since body fat mass mainly explained the difference in body weight gain and energy expenditure of adipose tissue is considered to be relatively low [29]. Total energy expenditure per mouse was significantly lower in WT mice on PUFA HFD than in WT mice on SAT HFD, but no significant difference was observed between the Gpr120 KO diet groups. The difference in total energy expenditure per mouse between WT mice given SAT HFD and WT mice given PUFA HFD could be explained by the lower body weight (see body weights at 10 weeks in Fig. 2) and similar body composition of the Gpr120 KO mice on SAT HFD as compared to WT mice on SAT HFD. Surprisingly, there was no detectable difference in energy expenditure related to lean body mass in spite of higher food
intake related to lean body mass and lower body weight gain in mice on PUFA
HFD. The measurements of energy expenditure were performed at thermoneu-
trality to avoid the influence of heat loss and therefore heat production. However,
all other experiments were performed at room temperature. It is possible that the
difference in energy expenditure between the mice on different diets was too small
to be detected by the system or that there had been a difference in energy
expenditure if the oxygen consumption had been measured at room temperature.
On the other hand, energy expenditure at thermoneutral temperature has been
shown to be increased by n-3 PUFA supplementation in a rat model [30]. Several
potential and non-exclusive mechanisms for increased energy expenditure
following n-3 PUFA diet have been described, including increased sodium and
calcium pump activities, increased mitochondrial proton leak and an enhanced
futile cycle in adipocytes involving lipolysis and re-esterification [14,31,32].
Therefore, a third possibility is that PUFA HFD triggered increased energy
expenditure mainly in the adipose tissue. Few studies have been performed in
humans on the effects of n-3 PUFA on energy metabolism but the available
evidence suggests that the effects are small and in line with previous results from
rodent studies [14]. For example, a cross-over study in healthy volunteers showed
that n-3 PUFA supplementation resulted in an increase in basal metabolic rate
and reduced adipose tissue mass [33].
A HFD enriched in n-3 PUFA or transgenic over expression of fat-1 have been
shown to improve glucose control in mice, including fasting plasma glucose,
glucose tolerance and several measures of insulin sensitivity [12,13,26,27,34,35]
reviewed in [14]. In human studies, n-3 PUFA supplementation often improves
glucose control in non-diabetics but the results are less clear in type 2 diabetes
[15]. Oh and co-workers showed that n-3 fatty acid supplementation for 5 weeks
resulted in improved glucose metabolism by improving insulin sensitivity in WT
but not in Gpr120 deficient mice [5]. The importance of GPR120 in the regulation
of insulin sensitivity was recently challenged [8]. Suckow et.al. showed that the
Gpr120 deficient mice have an enhanced glucagon secretion and sensitivity, which
better explained the deteriorated glucose control than worse insulin resistance.
Islet studies showed that Gpr120 deficiency enhanced arginine stimulated
glucagon secretion, while Gpr120 deficiency reduced glucagon response to DHA
and palmitic acid, which would indicate an improved glucose control in Gpr120
KO mice on HFD [8]. In our study, the PUFA HFD had similar effects on glucose
control in WT and Gpr120 deficient mice. If anything, the Gpr120 deficient mice
on PUFA HFD displayed a healthier phenotype including significantly lower
fasting glucose levels and a more marked insulin response at 15 minutes post
glucose challenge as compared to the SAT HFD.
Adipose tissue histology showed similar number of macrophages following
PUFA HFD as compared to SAT HFD. However, the distribution of macrophages
was markedly different with less CLS and less perilipin-free lipid droplets in the
adipose tissue of mice given the PUFA HFD as compared to mice given SAT HFD.
However, we did not observe any difference between the genotypes in terms of
CLS or presence of perilipin-free lipid droplets. The lower number of CLS
following treatment with n-3 PUFA as compared to a diet enriched in saturated fatty acids is in line with previous studies [5, 12, 36]. In contrast to our findings, these studies also showed reduced number of adipose tissue macrophages as a consequence of increase in n-3 PUFA [5, 12, 36]. Instead of a reduced number of macrophages, we observed that n-3 PUFA treatment resulted in accumulation of macrophages as multinuclear giant cells aggregation (MNGCA). The mechanism responsible for the n-3 PUFA induced aggregation of macrophages into multinuclear giant cells instead of prevention of migration of macrophages into the adipose tissue is at the present unknown. In summary, the n-3 PUFA enriched diet showed reduced number of CLS and dead adipocytes, while no apparent difference between WT and Gpr120 KO mice was observed.

We observed a markedly lower liver triglyceride content in mice on PUFA diet compared to the saturated/monounsaturated diet, independent of genotype. If anything, the liver lipid content was lower in the Gpr120 deficient than in WT animals fed PUFA diet. This result is in sharp contrast to the finding that Gpr120 deficient mice were refractory to the n-3 PUFA diet with respect to liver fat in another study [5]. We observed markedly higher plasma adiponectin levels in the mice given the PUFA-enriched diet, an effect in line with previous studies [26, 37]. Further, the effect was similar in WT and Gpr120 deficient mice. Adiponectin is an important regulator of glucose homeostasis and liver fat content [38, 39], and therefore is a plausible mediator of the positive effects of n-3 PUFA on glucose- and lipid metabolism.

The Langerhans islets in mice fed PUFA HFD were smaller and contained fewer macrophages than those from mice fed the SAT HFD. This effect was, if anything, more pronounced in the Gpr120 deficient mice. A number of factors might have contributed to this effect. First, body weight and total body fat was lower in the PUFA diet mice. Second, since glucose tolerance was improved in spite of reduced insulin response, the demand for insulin production and therefore that aspect of beta-cell stress was clearly reduced in mice given the PUFA diet as compared to the SAT HFD. Certainly, our results are consistent with the earlier work showing PUFA, or more specifically EPA, reduces the negative effects of long-chain saturated fatty acids on beta-cell function and survival [40]. Our results thus contrast with the study by Ichimura et.al. who reported that islets from Gpr120 deficient mice were larger than those from WT mice on HFD, probably reflecting the worse insulin sensitivity in those mice [6]. In this study, we found no evidence for larger islet size in the Gpr120 deficient mice than in WT animals, rather the opposite. Hence, the present results do not support negative effects of Gpr120 deficiency on islet health in vivo.

An obvious question is the extent to which the present study protocol differs from other published protocols suggesting the importance of GPR120 for glucose and energy metabolism and whether this might explain the differing results [5, 6] [8]. Oh et.al. switched from a 60 energy% saturated HFD to a 27% menhaden oil replacement of the HFD during 5 weeks resulting in 25 mol% EPA and DHA in plasma lipids whereas in our study the mice were given the n-3 PUFA enriched diet for 18 weeks and the diet resulted in 38–39 mol% EPA, DHA and ALA.
(C18:3n-3) of total fatty acids in plasma lipids. Thus, in our work, the menhaden diet was given in larger quantities during a longer period of time which might have resulted in a larger effect on body weight gain. It is well know that reduced body weight gain and increased energy expenditure will improve metabolic impairments. Hence, it is conceivable that the effect on body weight gain in PUFA HFD fed animals could have obscured other, subtle, effects on glucose control which occur as a result of Gpr120 deficiency. Two of the previously published Gpr120 KO mouse lines were developed on a mixed 129SV and C57BL/6 genetic background and it is not clear if and to what extent these lines were bred towards one genetic background [5, 6]. However, a recent study used mice from Taconic backcrossed onto C57Bl/6 for 6 generations [8]. The Gpr120 KO mouse line studied in this paper had a pure C57BL/6N genetic background and it is well established that the genetic background will affect the phenotype of experimental mice [41, 42]. Another technical factor is whether the DNA selection marker used to identify positive ES-cells is maintained or removed in the mice, as it is known that selection markers can influence phenotypes [43]. In the present study, the selection marker was removed from the Gpr120 KO mouse line by a Cre-LoxP breeding program. A third possible difference between the Gpr120 null mouse lines is the targeting strategy. The mice used by Oh et.al. and Suckow et.al. disrupted exon 2, whereas the line studied by Ichimura et.al and ourselves have targeted parts of exon 1. We ensured that no Gpr120 transcript was present in the Gpr120 deficient animals, either from exon 1 or from downstream exons, by designing the RT-PCR primers to amplify over the deleted DNA region as well as over exons 2–3. Moreover, the inhibition of glucose stimulated somatostatin secretion by a Gpr120 agonist occurred in WT animals, but was lost in Gpr120 KO animals [7], indicating lack of functional Gpr120 expression in our Gpr120 deficient model. Finally, the X-gal staining showed the expected tissue distribution as compared to mRNA expression of the receptor [2, 4–6] [1].

In summary, the present study shows that the major effects of n-3 PUFA diet on energy, lipid and energy metabolism, including any increases in plasma adiponectin levels, are not mediated by GPR120. However, we cannot exclude the possibility that there may be less pronounced effects of n-3 PUFA mediated by the GPR120 receptor that were not revealed in this study because of the marked effect of n-3 PUFA on energy metabolism.

**Supporting Information**

S1 Fig. (A) **Gpr120 gene targeting strategy.** Schematic diagram over the native 5′ region of Gpr120 gene, targeting vector, targeted allele and the disrupted Gpr120 gene. A region of 0.567 kb of the Gpr120 exon 1 CDS was replaced in frame with a nuclear βGal expression cassette followed a loxP floxed PGK neo selection marker. Filled rectangles indicate 5′ un-translated region (UTR), horizontal bar indicates probe used for southern blotting and triangles indicate loxP sites. (B) Southern blot analysis of the targeted ES clones. Genomic DNA was digested with SexAI or
SspI and probed with a probe shown in (A). Expected sizes of DNA fragments of the targeted allele are indicated in (A). Lane 1-6 represent targeted clones, lane 7 represent 1 kb marker.

doi:10.1371/journal.pone.0114942.s001 (TIF)

S2 Fig. Indirect calorimetry assessment. Energy expenditure assessed in kilocalories per hour per mouse (kcal/h) is shown in panel A for WT fed SAT HFD (n=8, filled square) and PUFA HFD (n=8, open square), and in panel B for Gpr120 KO mice fed SAT HFD (n=7, filled circle) and PUFA HFD (n=7, open circle). Energy expenditure relative to lean body mass (LBM) is shown in panel C for WT fed SAT HFD (n=8, filled square) and PUFA HFD (n=8, open square) and in panel D for Gpr120 KO mice fed SAT HFD (n=7, filled circle) and PUFA HFD (n=7, open circle). Thick black lines at the X-axis represent light off.

doi:10.1371/journal.pone.0114942.s002 (TIF)

S3 Fig. Adipose tissue histology. Representative slides of epididymal WAT stained for Mac2 (Macrophage 2 antigen, Galectin-3) from WT and Gpr120 KO mice fed either the SAT HFD or the PUFA HFD as indicated.

doi:10.1371/journal.pone.0114942.s003 (TIF)

S1 Table. Details of diet compositions and degree of lipid saturations in the PUFA and SAT HFD’s.

doi:10.1371/journal.pone.0114942.s004 (DOCX)

S1 Supplementary experimental procedures. Outlining details in experimental procedures

doi:10.1371/journal.pone.0114942.s005 (DOCX)

Acknowledgments

We would like to acknowledge Charlotte Lindgren and Anna-Cristine Carlsson for performing blood plasma analyses and Marie Jönsson for in vivo experimentation.

Author Contributions

Conceived and designed the experiments: MB LHS MBY JO. Performed the experiments: MB XX TA GB SL RN VMS DL. Analyzed the data: MB TA GB SL RN VMS NGM DL DMS MBY JO. Contributed reagents/materials/analysis tools: MB XX GB SL RN. Wrote the paper: MB YYL LHS MBY JO.

References

1. Sykaras AG, Demenis C, Case RM, McLaughlin JT, Smith CP (2012) Duodenal enteroendocrine I-cells contain mRNA transcripts encoding key endocannabinoid and fatty acid receptors. PLoS One 7: e42373.

2. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, et al. (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11: 90–94.

3. Duca FA, Swartz TD, Sakar Y, Covasa M (2012) Increased oral detection, but decreased intestinal signaling for fats in mice lacking gut microbiota. PLoS One 7: e39748.
4. Miyauchi S, Hirasawa A, Iga T, Liu N, Itsubo C, et al. (2009) Distribution and regulation of protein expression of the free fatty acid receptor GPR120. Naunyn Schmiedebergs Arch Pharmacol 379: 427–44.

5. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, et al. (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687–698.

6. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Harâ T, et al. (2012) Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483: 350–354.

7. Stone VM, Dhayal S, Brocklehurst KJ, Lenaghan C, Sorhede Winzell M, et al. (2014) GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of langerhans. Diabetologia.

8. Suckow AT, Polidori D, Yan W, Chon S, Ying Ma J, et al. (2014) Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: A role for GPR120 in glucagon secretion. J Biol Chem.

9. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, et al. (2003) The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278: 11303–11. Epub 2002 Dec 19.

10. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, et al. (2003) Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422: 173–176.

11. Burns RN, Moniri NH (2010) Agonism with the omega-3 fatty acids alpha-linolenic acid and docosahexaenoic acid mediates phosphorylation of both the short and long isoforms of the human GPR120 receptor. Biochem Biophys Res Commun 396: 1030–1035.

12. White PJ, Arita M, Taguchi R, Kang JX, Marett A (2010) Transgenic restoration of long-chain n-3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in insulin mice. Diabetes 59: 3066–3073.

13. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, et al. (1987) Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 237: 885−888.

14. Hulbert AJ, Turner N, Storlien LH, Else PL (2005) Dietary fats and membrane function: Implications for metabolism and disease. Biol Rev Camb Philos Soc 80: 155−169.

15. Carpentier YA, Portois L, Malaisse WJ (2006) N-3 fatty acids and the metabolic syndrome. Am J Clini Nutr 83: 1499S−1504S.

16. Bjursell M, Gerdin AK, Jonsson M, Surve VV, Svensson L, et al. (2006) G protein-coupled receptor 12 deficiency results in dyslipidemia and obesity in mice. Biochem Biophys Res Commun 348: 359−366.

17. Bjursell M, Admyre T, Goransson M, Marley AE, Smith DM, et al. (2011) Improved glucose control and reduced body fat mass in free fatty acid receptor 1-deficient mice fed a high-fat diet. Am J Physiol Endocrinol Metab 300: E211–20.

18. Gerdin AK, Surve VV, Jonsson M, Bjursell M, Bjorkman M, et al. (2006) Phenotypic screening of hepatocyte nuclear factor (HNF) 4-gamma receptor knockout mice. Biochemical & Biophysical Research Communications 349: 825−832.

19. Bjursell M, Gerdin AK, Ploj K, Svensson D, Svensson L, et al. (2006) Melanin-concentrating hormone receptor 1 deficiency increases insulin sensitivity in obese leptin-deficient mice without affecting body weight. Diabetes 55: 725−733.

20. Bjursell M, Ahnmark A, Bohlolly YM, William-Olsson L, Rhedin M, et al. (2007) Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 56: 583−93.

21. Lofgren L, Stahlman M, Forsberg GB, Saarinen S, Nilsson R, et al. (2012) The BUME method: A novel automated chloroform-free 96-well total lipid extraction method for blood plasma. J Lipid Res 53: 1690−1700.

22. Perez-Martinez P, Perez-Jimenez F, Lopez-Miranda J (2010) n-3 PUFA and lipotoxicity. Biochim Biophys Acta 1801: 362−366.

23. Mozaffarian D, Wu JH (2011) Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58: 2047−2067.

24. Superko HR, Superko SM, Nasir K, Agatston A, Garrett BC (2013) Omega-3 fatty acid blood levels: Clinical significance and controversy. Circulation 128: 2154−2161.
25. Huang XF, Xin X, McLennan P, Storlien L (2004) Role of fat amount and type in ameliorating diet-induced obesity: Insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression. Diabetes Obes Metab 6: 35–44.

26. Rossmeisl M, Jilkova ZM, Kuda O, Jelenik T, Medrikova D, et al. (2012) Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: Possible role of endocannabinoids. PLoS One 7: e38834.

27. Lamping KG, Nuno DW, Coppey LJ, Holmes AJ, Hu S, et al. (2013) Modification of high saturated fat diet with n-3 polyunsaturated fat improves glucose intolerance and vascular dysfunction. Diabetes Obes Metab 15: 144–152.

28. Kim EH, Bae JS, Hahn KB, Cha JY (2012) Endogenously synthesized n-3 polyunsaturated fatty acids in fat-1 mice ameliorate high-fat diet-induced non-alcoholic fatty liver disease. Biochem Pharmacol 84: 1359–1365.

29. Butler AA, Kozak LP (2010) A recurring problem with the analysis of energy expenditure in genetic models expressing lean and obese phenotypes. Diabetes 59: 323–329.

30. Janovska P, Flachs P, Kazdova L, Kopecy J (2013) Anti-obesity effect of n-3 polyunsaturated fatty acids in mice fed high-fat diet is independent of cold-induced thermogenesis. Physiol Res 62: 153–161.

31. Pan DA, Hulbert AJ, Storlien LH (1994) Dietary fats, membrane phospholipids and obesity. J Nutr 124: 1555–1565.

32. Flachs P, Rossmeisl M, Kuda O, Kopecy J (2013) Stimulation of mitochondrial oxidative capacity in white fat independent of UCP1: A key to lean phenotype. Biochim Biophys Acta 1831: 986–1003.

33. Couet C, Delarue J, Ritz P, Antoine JM, Lamisse F (1997) Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults. Int J Obes Relat Metab Disord 21: 637–643.

34. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, et al. (2006) Defining high-fat-diet rat models: Metabolic and molecular effects of different fat types. J Mol Endocrinol 36: 485–501.

35. Bellenger J, Bellenger S, Bataille A, Massey KA, Nicolaou A, et al. (2011) High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: Inflammatory pathway inhibition. Diabetes 60: 1090–1099.

36. Todoric J, Loffler M, Huber J, Bilban M, Reimers M, et al. (2006) Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49: 2109–2119.

37. Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, et al. (2009) Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: A role for resolvins and protectins. FASEB J 23: 1946–1957.

38. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947–953.

39. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, et al. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112: 91–100.

40. Kato T, Shimano H, Yamamoto T, Ishikawa M, Kumada K, et al. (2008) Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes 57: 2382–2392.

41. Doetschman T (2009) Influence of genetic background on genetically engineered mouse phenotypes. Methods Mol Biol 530: 423–433.

42. Threadgill DW, Drungvos AA, Hansen LA, Tennenbaum T, Lichti U, et al. (1995) Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 269: 230–234.

43. Scacheri PC, Crabtree JS, Novotny EA, Garrett-Beal L, Chen A, et al. (2001) Bidirectional transcriptional activity of PGK-neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice. Genesis 30: 259–263.